To Compare and See the effect of two species of ayurvedic herb sariva in the management of Mukhdushika (Acne Vulgaris)

Phase 2

• Conditions: Health Condition 1: L99- Other disorders of skin and subcutaneous tissue in diseases classified elsewhere

• Registration Number: CTRI/2024/07/070715
• Lead Sponsor: Kajal Dabas

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Voluntary males/females with sign and symptoms of Mukhdushika .

2. Patients from age group of 15-40 years will be selected.

3. No treatment of acne in past 10 days.

4. All skin types (greasy, normal) except sensitive skin.

5. Accepting not to use products with the same end benefits during the entire study duration.

6. Having signed a Consent Form and will be once informed orally and in writing of all information

concerning the study procedures and study objectives.

Exclusion Criteria

1. Patients having dermatological or any other medical problem such as folliculitis and boils or history

of allergic dermatitis.

2. Patients using any topical retinoid, topical and systemic steroids, throughout the duration of the

study.

3. Patients who are known cases of immune-compromised disease, uncontrolled diabetes, any

systemic illness which may interfere with study treatment and procedure.

4. Patients who are known cases of any malignancy.

5. Pregnant and lactating women and patients who are known cases of PCOD or any other

gynaecological problems.

6. Any known hypersensitivity to any cosmetic and raw material.

7. Subject in an exclusion period or participating in another similar cosmetic or therapeutic trial

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
-Efficacy will be checked through the GAGS score and subjective criteria after <br/ ><br>treatment period of 30 days. <br/ ><br>Timepoint: GAGS Score reduced during 30 days of treatment period

Secondary Outcome Measures

Name	Time	Method
Relapsing of the disease will be assessed in the follow up period that is 45th and <br/ ><br>60th day of our trial. <br/ ><br>-Changes in affected area will also be assessed.Timepoint: Follow up at 45th & 60th day of trial